A Resource for Healthcare and Social Services Professionals
Estimated time to complete: 2 hours
This training will prepare prescribers to handle practical considerations when treating patients with opioid use disorders in office settings. PLEASE NOTE: We will be posting an updated version of this training soon.
PLEASE NOTE: We will be posting an updated version of this training soon.
This training will provide prescribers the skills needed to actually implement office-based addiction treatment into an ambulatory practice setting. Additionally, this talk will provide expert, concrete tips to facilitate the provision of care for patients with substance use disorders utilizing medications in their treatment.
This training is held as a recorded training. Participants must complete a pre-test, post-test, and post-evaluation to receive credit for attending the training. Participants must score a 7/10 on the post-test. A certificate of credit will be able to be downloaded following successful completion of the requirements above.
Prescribers who have recently obtained their X-Waiver (or who are contemplating getting their waiver) and are looking to increase provision of care for patients with substance use disorder in an outpatient setting.
---- ----
Dan Alford, MD, CME Course Director
Ilana Hardesty, MA, Planning Committee
Colleen LaBelle, MSN, RN-BC, CARN, Planning Committee
Conor Monks, Planning Committee
Members of the planning committee have no relevant financial relationships to disclose.
Charmaine Lastimoso, MPH, MSN, NP-C, CARN-AP
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Annie Potter, MSN, MPH, NP, CARN-AP
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Kristin Wason, MSN, NP-C, CARN
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
The learner will be able to:
Identify patients appropriate for a trial of buprenorphine treatment.
Recognize the benefits of providing low barrier access to care.
Discuss the utility of toxicology screening.
Describe examples of a harm reduction approach to managing care for persons with opioid use disorder.
Boston Medical Center Grayken Center for Addiction TTA, Department of Public Health, Bureau of Substance Addiction Services (BSAS), Opioid Response Network (ORN)
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement
Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Release: 3/8/2021
Date of Most Recent Review: 3/9/2022
Date of Expiration: 3/8/2023
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.